BACKGROUND & AIMS: The factors associated with adverse outcome from hepatitis C virus (HCV) infection are incompletely understood. To determine the incidence and risk factors associated with the development of end-stage liver disease (ESLD) and liver-related death (LRD), we conducted a retrospective/prospective population-based study in a cohort of Alaska Native persons chronically infected with HCV from 1994 to 2005. METHODS: We followed 960 persons prospectively for an average of 7.2 years and retrospectively for 12.1 years with data from medical records and serum samples. We compared data from subjects that were chronically infected with those who recovered from HCV infection, stratified by alcohol use. Survival models were used to examine factors associated with ESLD and LRD in chronically infected patients. RESULTS: During prospective follow-up, 80 (8.8%) and 47 (5.2%) patients developed ESLD and LRD, respectively. In examining incidence per 100 person-years, no difference was found among heavy alcohol users in the incidence of LRD (2.28 versus 3.50; P = .34) or ESLD (3.21 versus 5.69; P = .13) in persons with chronic HCV compared with those recovered from HCV infection. In subjects that consumed <50 g alcohol/d, the incidences of LRD were 0.77 and 0.09 (P = .01) and of ESLD were 1.58 versus 0.36 (P = .002), respectively, in subjects with chronic infection versus those that recovered. Multivariate analysis showed that older age, heavy alcohol use, and HCV genotype 3 were associated with ESLD. CONCLUSIONS: A history of heavy alcohol use is associated with the highest incidence of LRD and ESLD, regardless of whether patients are chronically infected or recover from HCV infection. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: The factors associated with adverse outcome from hepatitis C virus (HCV) infection are incompletely understood. To determine the incidence and risk factors associated with the development of end-stage liver disease (ESLD) and liver-related death (LRD), we conducted a retrospective/prospective population-based study in a cohort of Alaska Native persons chronically infected with HCV from 1994 to 2005. METHODS: We followed 960 persons prospectively for an average of 7.2 years and retrospectively for 12.1 years with data from medical records and serum samples. We compared data from subjects that were chronically infected with those who recovered from HCV infection, stratified by alcohol use. Survival models were used to examine factors associated with ESLD and LRD in chronically infected patients. RESULTS: During prospective follow-up, 80 (8.8%) and 47 (5.2%) patients developed ESLD and LRD, respectively. In examining incidence per 100 person-years, no difference was found among heavy alcohol users in the incidence of LRD (2.28 versus 3.50; P = .34) or ESLD (3.21 versus 5.69; P = .13) in persons with chronic HCV compared with those recovered from HCV infection. In subjects that consumed <50 g alcohol/d, the incidences of LRD were 0.77 and 0.09 (P = .01) and of ESLD were 1.58 versus 0.36 (P = .002), respectively, in subjects with chronic infection versus those that recovered. Multivariate analysis showed that older age, heavy alcohol use, and HCV genotype 3 were associated with ESLD. CONCLUSIONS: A history of heavy alcohol use is associated with the highest incidence of LRD and ESLD, regardless of whether patients are chronically infected or recover from HCV infection. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Dana J T Bruden; Brian J McMahon; Lisa Townshend-Bulson; Prabhu Gounder; Jim Gove; Julia Plotnik; Chriss Homan; Annette Hewitt; Youssef Barbour; Philip R Spradling; Brenna C Simons; Susan McArdle; Michael Bruce Journal: Hepatology Date: 2017-05-22 Impact factor: 17.425
Authors: Anil Suryaprasad; Kathy K Byrd; John T Redd; David G Perdue; M Michele Manos; Brian J McMahon Journal: Am J Public Health Date: 2014-04-22 Impact factor: 9.308
Authors: Risha Irvin; Geetanjali Chander; Kathleen M Ward; Sean Manogue; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; David L Thomas; Shruti H Mehta; Mark S Sulkowski Journal: J Viral Hepat Date: 2020-01-07 Impact factor: 3.728
Authors: Bryce D Smith; Geoff A Beckett; Anthony Yartel; Deborah Holtzman; Nita Patel; John W Ward Journal: Am J Public Health Date: 2014-01-16 Impact factor: 9.308
Authors: Brian J McMahon; Dana Bruden; Lisa Townshend-Bulson; Brenna Simons; Phillip Spradling; Stephen Livingston; James Gove; Annette Hewitt; Julia Plotnik; Chriss Homan; Hannah Espera; Susan Negus; Mary Snowball; Youssef Barbour; Michael Bruce; Prabhu Gounder Journal: Clin Gastroenterol Hepatol Date: 2016-10-17 Impact factor: 11.382
Authors: Bryce D Smith; Anthony K Yartel; Katherine Krauskopf; Omar I Massoud; Kimberly A Brown; Michael B Fallon; David B Rein Journal: Clin Infect Dis Date: 2015-01-16 Impact factor: 9.079
Authors: Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Noya Galai; Jonathan Washington; Yvonne Higgins; Ashwin Balagopal; David L Thomas Journal: Ann Intern Med Date: 2013-05-07 Impact factor: 25.391